Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,236 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Asthma; Eosinophilic, Asthma
Interventions: Lipopolysaccharides; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
Interventions: Invariant Natural Killer T Cell Therapy; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sleep
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Risk Presentation Format, Frequently Asked Questions Exposure; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 39 Years to 74 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatic Impairment
Interventions: AZD4144; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Mesa, Arizona • Miami Lakes, Florida • Orlando, Florida + 1 more

Conditions: Bacterial Infections
Interventions: Likmez® (metronidazole) Oral Suspension; Drug
Lead sponsor: Saptalis Pharmaceuticals LLC; Industry
Eligibility: 12 Months to 4 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Richmond, Texas

Conditions: Chronic Disease, Mental Health, Caridovascular Disease, Stress, Adolescent Health
Interventions: Tools for Arctic Health Promotion; Behavioral
Lead sponsor: University of Alaska Fairbanks; Other
Eligibility: 12 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fairbanks, Alaska

Conditions: Spine Surgery, Intraoperative Hypotension, Tissue Perfusion
Interventions: Phenylephrine hydrochloride infusion, Norepinephrine bitartrate infusion; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depression, Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage III Colorectal Cancer, Stage II Colorectal Cancer, Stage I Colorectal Cancer
Interventions: MINDSET, Enhanced Usual Care (EUC); Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioma
Interventions: [18F]FMISO-PET with contrast-enhanced MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glioblastoma
Interventions: B-cell vaccination; Biological
Lead sponsor: Catalina Lee Chang; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pancreatitis, Chronic Pancreatitis, Acute Pancreatitis (AP), Recurrent Acute Pancreatitis
Interventions: Varenicline (VAR); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: GLP-1, Alcohol
Interventions: Acute Ethanol Dose; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Urologic Diseases, Male Urogenital Diseases, Penile Diseases, Corpus Callosum Malformation, Corpora Cavernosa; Inflammation, Trauma Injury
Interventions: Autologous tissue engineered corpora; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Epilepsy, Neurologic Disorder
Interventions: Cenobamate; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke
Interventions: Screener, Standard of care; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions: 18F-FAPI-74, 18F-FDG, PET/CT; Drug · Procedure
Lead sponsor: Randy Yeh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Sepsis, Burn, Inflammation, Burn Infection
Interventions: PSP Monitoring; Device
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Schizophrenia
Interventions: 14C-SEP-380135; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Urethral Stricture, Urethral Diseases
Interventions: Tranexamic Acid, Urethroplasty; Drug · Procedure
Lead sponsor: Amjad Alwaal, MD, MSc, FRCSC, FACS; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Autism, Suicide Prevention
Interventions: Safety Planning Intervention, Crisis Interventions for Pediatric Providers - Autism version (CIPP-A); Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: LY4167586, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Anaheim, California • Los Alamitos, California • Walnut Creek, California + 8 more

Conditions: PTSD - Post Traumatic Stress Disorder, Substance Use
Interventions: Adapted Cognitive Behavioral Intervention for Trauma in Schools (CBITS) with a Racial Trauma Module (RTM); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

BLinatumomab and iNKT in Relapsed B-Cell ALL

Stress, Coping, and Sleep Health Study

Effects of Risk Presentation Format and Frequently Asked Questions on Breast Cancer Risk Skepticism

A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health

Superiority of Phenylephrine Versus Norepinephrine in Complex Spine Surgery (SPiNeS)

ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

Varenicline for Smoking Cessation in Pancreatitis

Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics

Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora

Cenobamate in the Intensive Care Unit

Reduce Inefficiencies in Management of Spasticity

Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET

Sepsis Biomarker Monitoring in Burn Patients

A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

REDUCER Trial (TXA in Urethroplasty)

Crisis Interventions for Pediatric Providers - Autism Version

A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes

CBITS-RTM Pilot Study